Aug. 27, 2025 — Royal Philips has released Transcend Plus, the next generation of its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image quality and artificial intelligence (AI), including newly FDA-cleared 2D and 3D image quality enhancements and a growing suite of AI-enabled clinical applications — all designed to meet the growing challenges of cardiac care.

Aug. 25, 2025 — Amgen has announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as "bad cholesterol." The update removes a prior requirement for a patient to have been diagnosed with cardiovascular (CV) disease.

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain, Aug. 29-Sept. 1. Data presented at ESC include Merck’s latest research focusing on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF).

Aug. 21, 2025 — Boston Scientific has initiated the AGENT DCB STANCE trial to assess the safety and effectiveness of the AGENT Drug-Coated Balloon (DCB) compared to the standard of care – percutaneous coronary intervention (PCI) treatment with drug-eluting stents (DES) and/or balloon angioplasty – in patients with de novo (previously untreated) coronary lesions.

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as Broken Heart syndrome — is a serious and sometimes fatal heart condition increasingly reported in intensive care units (ICUs). Yet without a clear clinical pathway in ICUs, it’s often missed, putting critically ill patients at risk.

Aug. 19, 2025 — Openwater, an open-source medical technology company delivering portable, hospital-grade diagnostic and therapeutic devices, recently announced the University of Birmingham in the United Kingdom is the first to receive the latest version of Openwater’s Open-Motion device. The university’s clinical research team plans to use the technology in a new trial studying stroke rehabilitation in patients experiencing loss of movement. 

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for lipoprotein(a) [Lp(a)], a largely overlooked genetic marker for cardiovascular risk, could significantly enhance early detection of heart disease and reduce long-term healthcare costs.

Aug. 18, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons, has identified early hemodynamic valve deterioration (HVD) in more than 6% of patients just one year after undergoing transcatheter aortic valve implantation (TAVI), raising new questions about valve durability in younger, lower-risk populations.

Aug. 18, 2025 — iRhythm Technologies, Inc. has announced the publication of a real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries (AVALON) in the American Journal of Managed Care reinforcing the clinical performance of the Zio long-term continuous monitoring (LTCM) service.

Aug. 19, 2025 — In a move to advance stroke care and accelerate critical decision-making, Tift Regional Medical Center (TRMC) has implemented RapidAI’s deep clinical AI platform, bringing faster insights and improved coordination to stroke response teams. The technology is now live across TRMC’s stroke program and is already helping clinicians deliver more timely and informed care.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now